Kate Murray, Lucy Oldfield, Irena Stefanova, Manuel Gentiluomo, Paolo Aretini, Rachel O'Sullivan, William Greenhalf, Salvatore Paiella, Mateus N Aoki, Aldo Pastore, James Birch-Ford, Bhavana Hemantha Rao, Pinar Uysal-Onganer, Caoimhe M Walsh, George B Hanna, Jagriti Narang, Pradakshina Sharma, Daniele Campa, Cosmeri Rizzato, Andrei Turtoi, Elif Arik Sever, Alessio Felici, Ceren Sucularli, Giulia Peduzzi, Elif Öz, Osman Uğur Sezerman, Robert Van der Meer, Nathan Thompson, Eithne Costello
Semin Cancer Biol . 2025 Jun:111:76-88. doi: 10.1016/j.semcancer.2025.02.009. Epub 2025 Feb 20.
Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed in its late stages when treatment options are limited. Unlike other common cancers, there are no population-wide screening programmes for PDAC. Thus, early disease detection, although urgently needed, remains elusive. Individuals in certain high-risk groups are, however, offered screening or surveillance. Here we explore advances in understanding high-risk groups for PDAC and efforts to implement biomarker-driven detection of PDAC in these groups. We review current approaches to early detection biomarker development and the use of artificial intelligence as applied to electronic health records (EHRs) and social media. Finally, we address the cost-effectiveness of applying biomarker strategies for early detection of PDAC.